Latest News and Press Releases

SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the...

Myriad Genetics announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.

Myriad Genetics announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment.

Myriad Genetics announces senior leadership transition; Sam Raha as CEO and Mark S. Verratti as COO effective April 30, 2025.

Myriad Genetics today announced financial results for its fourth quarter and full-year ended December 31, 2024.

Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.

Myriad Genetics has been named on the Forbes list of America’s Best Employers 2025.

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025.